Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immu...

Full description

Saved in:
Bibliographic Details
Published inJournal of biomedical science Vol. 31; no. 1; p. 5
Main Authors Li, Yan-Ruide, Halladay, Tyler, Yang, Lili
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 12.01.2024
BioMed Central
BMC
Subjects
Antigen presentation
Antigens
Apoptosis
Cancer
Cancer therapies
CAR-engineered T (CAR-T) cell therapy
Care and treatment
Cell death
Cell therapy
Cell-based immunotherapies (CBIs)
Chimeric antigen receptor (CAR)
Chimeric antigen receptors
Cytotoxicity
Development and progression
Down-regulation
Genetic engineering
Health aspects
Humans
Immune checkpoint
Immune checkpoint proteins
Immune Evasion
Immune system
Immunosuppression
Immunotherapy
Immunotherapy, Adoptive
Ligands
Lymphocytes
Metastasis
Mutation
Neoplasms - therapy
Peptides
Prospective Studies
Proteins
Receptors, Chimeric Antigen - metabolism
Tumor cells
Tumor Microenvironment
Tumor microenvironment (TME)
Tumors
Tumor microenvironment (TME)
Tumor heterogeneity
Chimeric antigen receptor (CAR)
Immune evasion
CAR-engineered T (CAR-T) cell therapy
Cell-based immunotherapies (CBIs)
Immune checkpoint proteins
Online AccessGet full text

Cover

Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immune evasion, thereby circumventing the impact of CBIs. This phenomenon is facilitated by an intricately immunosuppression entrenched within the tumor microenvironment (TME). Principal mechanisms underpinning tumor immune evasion from CBIs encompass loss of antigens, downregulation of antigen presentation, activation of immune checkpoint pathways, initiation of anti-apoptotic cascades, and induction of immune dysfunction and exhaustion. In this review, we delve into the intrinsic mechanisms underlying the capacity of tumor cells to resist CBIs and proffer prospective stratagems to navigate around these challenges.
AbstractList Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immune evasion, thereby circumventing the impact of CBIs. This phenomenon is facilitated by an intricately immunosuppression entrenched within the tumor microenvironment (TME). Principal mechanisms underpinning tumor immune evasion from CBIs encompass loss of antigens, downregulation of antigen presentation, activation of immune checkpoint pathways, initiation of anti-apoptotic cascades, and induction of immune dysfunction and exhaustion. In this review, we delve into the intrinsic mechanisms underlying the capacity of tumor cells to resist CBIs and proffer prospective stratagems to navigate around these challenges.
Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immune evasion, thereby circumventing the impact of CBIs. This phenomenon is facilitated by an intricately immunosuppression entrenched within the tumor microenvironment (TME). Principal mechanisms underpinning tumor immune evasion from CBIs encompass loss of antigens, downregulation of antigen presentation, activation of immune checkpoint pathways, initiation of anti-apoptotic cascades, and induction of immune dysfunction and exhaustion. In this review, we delve into the intrinsic mechanisms underlying the capacity of tumor cells to resist CBIs and proffer prospective stratagems to navigate around these challenges.
Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immune evasion, thereby circumventing the impact of CBIs. This phenomenon is facilitated by an intricately immunosuppression entrenched within the tumor microenvironment (TME). Principal mechanisms underpinning tumor immune evasion from CBIs encompass loss of antigens, downregulation of antigen presentation, activation of immune checkpoint pathways, initiation of anti-apoptotic cascades, and induction of immune dysfunction and exhaustion. In this review, we delve into the intrinsic mechanisms underlying the capacity of tumor cells to resist CBIs and proffer prospective stratagems to navigate around these challenges. Keywords: Immune evasion, Cell-based immunotherapies (CBIs), Chimeric antigen receptor (CAR), CAR-engineered T (CAR-T) cell therapy, Tumor microenvironment (TME), Immune checkpoint proteins, Tumor heterogeneity
Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immune evasion, thereby circumventing the impact of CBIs. This phenomenon is facilitated by an intricately immunosuppression entrenched within the tumor microenvironment (TME). Principal mechanisms underpinning tumor immune evasion from CBIs encompass loss of antigens, downregulation of antigen presentation, activation of immune checkpoint pathways, initiation of anti-apoptotic cascades, and induction of immune dysfunction and exhaustion. In this review, we delve into the intrinsic mechanisms underlying the capacity of tumor cells to resist CBIs and proffer prospective stratagems to navigate around these challenges.
ArticleNumber 5
Audience Academic
Author Li, Yan-Ruide
Halladay, Tyler
Yang, Lili
Author_xml – sequence: 1
  givenname: Yan-Ruide
  surname: Li
  fullname: Li, Yan-Ruide
  email: charlie.li@ucla.edu
  organization: Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA. charlie.li@ucla.edu
– sequence: 2
  givenname: Tyler
  surname: Halladay
  fullname: Halladay, Tyler
  organization: Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA
– sequence: 3
  givenname: Lili
  surname: Yang
  fullname: Yang, Lili
  email: liliyang@ucla.edu, liliyang@ucla.edu, liliyang@ucla.edu, liliyang@ucla.edu
  organization: Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, 90095, USA. liliyang@ucla.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38217016$$D View this record in MEDLINE/PubMed
BookMark eNptUk1vFSEUnZga-6F_wIWZxI2bqcAMw8Vd06h9SRM36pYwcHnlZQaeMNOk_768Tm3VCAvI5ZwD93BOq6MQA1bVW0rOKYX-Y6ZMMtkQ1jWESAkNvKhOaMfahlAmjv7YH1enOe8IoVyCeFUdt8CoILQ_qX5upmkJWOOtzj6G2ofa4Dg2g85oa384jPMNJr2_-1QvIelbHH3Y1uZGjyOGLeZaB1uHWOp1npOecesxv65eOj1mfPO4nlU_vnz-fnnVXH_7urm8uG4MJzA3g9SCQG_QgbbADZcdaOgAWg7alGGdHTpjQXDBRAe9dGgHJyn2vRGybc-qzapro96pffKTTncqaq8eCjFtlU6zNyMqFJYNZiDQAnbOIZCBGC257Tjn2Omi9WHV2qf4a8E8q8nngxk6YFyyYrL4yVnxvEDf_wPdxSWF0umKgp5y-oza6nK_Dy4Wf8xBVF2I8gOyo0AK6vw_qDItTt6UH3e-1P8isJVgUsw5oXvqmxJ1CIZag6FKMNRDMBQU0rvHFy_DhPaJ8jsJ7T3C1bRS
CitedBy_id crossref_primary_10_1080_21691401_2024_2347377
crossref_primary_10_1186_s12575_024_00245_2
crossref_primary_10_20517_2394_4722_2024_38
crossref_primary_10_3389_fimmu_2024_1392546
crossref_primary_10_3390_cancers16132478
crossref_primary_10_3390_biology13030196
crossref_primary_10_1021_acs_jcim_4c00455
crossref_primary_10_3390_biology13050307
Cites_doi 10.1111/his.12079
10.1172/jci.insight.133977
10.1038/nrclinonc.2017.166
10.1146/annurev.immunol.23.021704.115526
10.1182/blood.2020005123
10.1182/bloodadvances.2021006418
10.20944/preprints202102.0150.v1
10.1002/j.1460-2075.1992.tb05481.x
10.1016/j.celrep.2017.09.002
10.1111/bjh.13562
10.15252/embr.201439246
10.3389/fimmu.2023.1140541
10.4049/jimmunol.173.7.4352
10.1038/ncomms12320
10.1126/science.aaa8172
10.3390/ijms21010157
10.1182/blood.2019000017
10.1038/415536a
10.3390/cancers13164178
10.1124/mol.65.3.711
10.1038/s41591-018-0146-z
10.1182/blood-2017-06-793141
10.1182/blood-2018-99-112572
10.1186/s13045-019-0746-1
10.3389/fimmu.2020.01217
10.1016/S1074-7613(00)80543-9
10.1038/cddis.2015.162
10.1016/j.tranon.2022.101342
10.1038/s41591-018-0201-9
10.1016/S0006-2952(03)00158-8
10.4049/jimmunol.1800033
10.1038/35069118
10.1158/0008-5472.CAN-07-0082
10.1146/annurev.immunol.24.021605.090737
10.1097/CJI.0b013e3181ee6675
10.1038/leu.2014.215
10.1038/s41598-017-00462-8
10.1186/s10020-021-00383-3
10.1182/blood-2016-05-718395
10.1016/j.ymthe.2018.05.003
10.1038/s41591-021-01497-1
10.3389/fimmu.2023.1206441
10.1111/j.1365-2567.2010.03255.x
10.1007/s11060-008-9601-x
10.1158/2159-8290.CD-15-1020
10.1200/JCO.2014.57.3329
10.1182/blood-2020-140907
10.1007/s40259-017-0247-0
10.1038/s41467-021-21168-6
10.1016/j.stem.2012.05.007
10.1111/imr.12520
10.1038/s41577-019-0223-7
10.1038/s41586-023-05778-2
10.1038/s41591-022-01726-1
10.1172/JCI85309
10.1002/eji.201948457
10.1126/scitranslmed.3003130
10.1080/2162402X.2017.1364828
10.1016/S0002-9440(10)63238-5
10.1038/ni.2035
10.1146/annurev.immunol.25.022106.141609
10.1016/S0140-6736(14)61403-3
10.3389/fimmu.2022.999549
10.1016/j.ccell.2019.09.006
10.1158/0008-5472.CAN-13-2563
10.1038/s41375-019-0580-z
10.1158/1078-0432.CCR-18-0426
10.1084/jem.20100643
10.3390/biom12060850
10.1186/s13045-021-01209-9
10.1097/CJI.0000000000000169
10.1016/j.coph.2020.07.002
10.1038/nm.3833
10.1038/s41417-020-00284-3
10.1242/jcs.112.4.491
10.1158/2159-8290.CD-18-0442
10.4049/jimmunol.173.3.1731
10.1172/JCI87366
10.1016/S0167-5699(00)01692-3
10.1158/1078-0432.CCR-13-0458
10.3390/cells11091583
10.1186/1756-8722-6-74
10.1158/1078-0432.CCR-11-0351
10.1093/jnci/djt184
10.1038/nrrheum.2009.184
10.1172/JCI83092
10.1182/blood-2004-06-2482
10.1038/nri3904
10.18632/oncotarget.27870
10.1182/blood-2015-08-665547
10.1038/s43018-022-00484-w
10.1038/s41571-019-0297-y
10.1038/s41419-019-1568-3
10.1016/j.ejca.2016.09.010
10.1172/JCI126397
10.1038/s41591-018-0010-1
10.1038/ncponc0666
10.4049/jimmunol.178.9.5552
10.1016/j.phrs.2022.106329
10.1182/blood-2015-12-629089
10.1038/nm.4241
10.1038/nm0198-043
10.1038/s41591-020-1081-3
10.1126/science.aay5967
10.3324/haematol.2009.008862
10.1016/j.ymthe.2018.09.008
10.1016/S0065-230X(01)83005-0
10.1016/j.coi.2015.12.007
10.1158/1078-0432.CCR-13-2627
10.3390/cancers14112749
10.4161/epi.22901
10.1182/blood-2017-06-741033
10.1182/blood-2015-12-686725
10.1182/blood-2005-11-4742
10.1038/s41422-020-0343-4
10.1016/j.immuni.2007.05.016
10.1158/1535-7163.MCT-09-0583
10.1016/j.cub.2020.06.081
10.1038/s41551-018-0235-9
10.1038/35069112
10.2147/OTT.S220196
10.1038/s41573-019-0052-1
10.1038/s41586-022-05593-1
10.1038/nrc3239
10.1126/scitranslmed.aaf8621
10.1038/s41409-020-01134-4
10.1186/s13045-018-0582-8
10.1038/nrc.2017.86
10.3389/fimmu.2021.627764
10.1038/s41467-021-23331-5
10.3389/fonc.2020.590941
10.1038/s41392-020-0110-5
10.1038/s41551-023-01084-4
10.1084/jem.20100637
10.1172/JCI125423
10.1038/s41591-022-01765-8
10.1038/leu.2010.75
10.1038/s41419-017-0061-0
10.1016/j.ymthe.2022.11.019
10.1016/j.jcyt.2013.01.002
10.1038/s41467-021-21177-5
10.1136/jitc-2020-001150
10.1186/s13045-019-0760-3
10.1038/s41573-019-0051-2
10.1016/j.biopha.2019.109625
10.1016/j.scib.2020.12.027
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7QL
7QO
7QP
7T5
7TK
7TM
7U7
7U9
7X7
7XB
88E
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
8G5
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
L6V
LK8
M0S
M1P
M2O
M7N
M7P
M7S
MBDVC
P64
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
PTHSS
Q9U
RC3
7X8
DOA
DOI 10.1186/s12929-024-00998-8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
Health Research Premium Collection
Natural Science Collection
Biological Science Collection
ProQuest Medical Library (Alumni)
Engineering Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
Technology Collection
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central Basic
Toxicology Abstracts
ProQuest SciTech Collection
ProQuest Medical Library
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic


MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1423-0127
EndPage 5
ExternalDocumentID oai_doaj_org_article_e7d2bcb0838e4ffe80b0ca95d4555e4a
A782194180
10_1186_s12929_024_00998_8
38217016
Genre Journal Article
Review
GrantInformation_xml – fundername: University of California, Los Angeles
  grantid: UCLA BSCRC Innovation Award
– fundername: University of California, Los Angeles
  grantid: MIMG M. John Pickett Post-Doctoral Fellow Award
– fundername: University of California, Los Angeles
  grantid: Ablon Scholars Award
– fundername: University of California, Los Angeles
  grantid: CIRM-BSCRC Postdoctoral Fellowship
GroupedDBID ---
-A0
.86
0R~
29J
29K
2NJ
2WC
36B
3V.
4.4
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
AAFWJ
ABDBF
ABJCF
ABOCM
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACRMQ
ADBBV
ADIMF
ADINQ
ADRAZ
ADUKV
AEAQA
AEGNC
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
B0M
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BGLVJ
BGNMA
BHPHI
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
CYUIP
D-I
DIK
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
ECM
EIF
EMB
EMK
EMOBN
EPL
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHE
IHR
INH
INR
ITC
IZQ
KDC
KQ8
L6V
LAK
LK8
M1P
M2O
M48
M4Y
M7P
M7S
ML~
M~E
NPM
NU0
O5R
O5S
OK1
P19
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
RBZ
RHV
RNS
ROL
RPM
RPX
RRX
RSV
S1Z
S27
SBL
SDH
SOJ
SV3
T13
TR2
TUS
UKHRP
VC2
WJK
WK8
~8M
~KM
AAYXX
CITATION
53G
ABVAZ
AFGXO
AFNRJ
7QL
7QO
7QP
7T5
7TK
7TM
7U7
7U9
7XB
8FD
8FK
C1K
FR3
H94
K9.
M7N
MBDVC
P64
PQEST
PQUKI
PRINS
Q9U
RC3
7X8
ID FETCH-LOGICAL-c508t-b9a7086cef8ad85c5948a8488358accccdfdb4cd8757274869fedbf91e66c7933
IEDL.DBID 8FG
ISSN 1423-0127
1021-7770
IngestDate Tue Oct 22 15:07:12 EDT 2024
Sat Oct 26 01:37:11 EDT 2024
Thu Oct 10 17:42:41 EDT 2024
Fri Feb 23 00:20:25 EST 2024
Tue Nov 12 23:44:06 EST 2024
Thu Sep 12 18:15:00 EDT 2024
Sat Nov 02 12:29:36 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Tumor microenvironment (TME)
Tumor heterogeneity
Chimeric antigen receptor (CAR)
Immune evasion
CAR-engineered T (CAR-T) cell therapy
Cell-based immunotherapies (CBIs)
Immune checkpoint proteins
Language English
License 2024. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-b9a7086cef8ad85c5948a8488358accccdfdb4cd8757274869fedbf91e66c7933
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://www.proquest.com/docview/2914286151?pq-origsite=%requestingapplication%
PMID 38217016
PQID 2914286151
PQPubID 54111
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_e7d2bcb0838e4ffe80b0ca95d4555e4a
proquest_miscellaneous_2914252292
proquest_journals_2914286151
gale_infotracmisc_A782194180
gale_infotracacademiconefile_A782194180
crossref_primary_10_1186_s12929_024_00998_8
pubmed_primary_38217016
PublicationCentury 2000
PublicationDate 2024-01-12
PublicationDateYYYYMMDD 2024-01-12
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-12
  day: 12
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Basel
PublicationTitle Journal of biomedical science
PublicationTitleAlternate J Biomed Sci
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References N Shimasaki (998_CR2) 2020; 19
J Fischer (998_CR20) 2017; 40
C Sun (998_CR10) 2016; 127
Y Liu (998_CR84) 2022; 17
JA Marin-Acevedo (998_CR33) 2018; 11
G Gerlini (998_CR60) 2004; 165
G Enblad (998_CR149) 2018; 24
L Cherkassky (998_CR119) 2016; 126
M Kurte (998_CR61) 2004; 173
L Jin (998_CR109) 2021; 66
DJJ Powell (998_CR141) 2005; 105
D Vijayan (998_CR99) 2017; 17
998_CR146
KC Conlon (998_CR92) 2015; 33
T Rabilloud (998_CR14) 2021; 12
LJ Rupp (998_CR103) 2017; 7
VA Fabrizio (998_CR126) 2022; 6
K Reinhard (998_CR128) 2020; 367
L Gattinoni (998_CR142) 2017; 23
J Fourcade (998_CR45) 2010; 207
JA Craddock (998_CR111) 2010; 33
M Ruella (998_CR51) 2018; 24
H-W Bernd (998_CR25) 2009; 94
SM Sagnella (998_CR113) 2022; 182
Y Yao (998_CR47) 2008; 89
AV Finck (998_CR5) 2022; 28
OC Finney (998_CR136) 2019; 129
HJ Pegram (998_CR89) 2015; 29
ML Davila (998_CR6) 2022; 3
LG Daenen (998_CR129) 2009; 8
EF Lee (998_CR50) 2019; 10
B Agrawal (998_CR63) 1998; 4
M Ruella (998_CR144) 2017; 31
998_CR132
SF Lacey (998_CR138) 2013; 15
K Hwang (998_CR78) 2013; 62
DE Lukashev (998_CR101) 2003; 65
F Garrido (998_CR24) 2016; 39
998_CR83
B Hu (998_CR88) 2017; 20
JP Leonard (998_CR91) 1997; 90
JE Visvader (998_CR69) 2012; 10
MR Nazareth (998_CR118) 2007; 178
VS Sheth (998_CR145) 2021; 56
M de Charette (998_CR22) 2016; 68
A Kallies (998_CR134) 2020; 20
Y-R Li (998_CR104) 2022; 14
KA Hay (998_CR148) 2017; 130
I Dagogo-Jack (998_CR12) 2018; 15
LL Lanier (998_CR30) 2005; 23
RA Roberts (998_CR26) 2006; 108
E Jacoby (998_CR57) 2016; 7
MO Li (998_CR59) 2006; 24
Y-R Li (998_CR64) 2022; 13
P Allavena (998_CR71) 2021; 27
V Hoyos (998_CR87) 2010; 24
S Simon (998_CR41) 2017; 7
Q Zhang (998_CR56) 2020; 136
MK Samur (998_CR17) 2021; 12
AX Wang (998_CR125) 2023; 14
DW Lee (998_CR147) 2015; 385
C DeSelm (998_CR123) 2018; 26
S Depil (998_CR3) 2020; 19
MJ Butte (998_CR115) 2007; 27
B Rowshanravan (998_CR34) 2018; 131
R Hong (998_CR131) 2021; 12
AG Evans (998_CR55) 2015; 171
P Leone (998_CR27) 2013; 105
NL de Vries (998_CR85) 2023; 613
I Caruana (998_CR112) 2015; 21
M Mirabet (998_CR102) 1999; 112
F Braig (998_CR32) 2017; 129
B Aramini (998_CR72) 2021; 12
Y Liu (998_CR93) 2019; 203
MB Schaaf (998_CR107) 2018; 9
LB John (998_CR120) 2013; 19
JS Yi (998_CR135) 2010; 129
L Shi (998_CR42) 2013; 6
Z Ge (998_CR74) 2020; 10
L Labanieh (998_CR7) 2018; 2
JC Schwartz (998_CR36) 2001; 410
MW Pickup (998_CR67) 2014; 15
Y Jiang (998_CR76) 2015; 6
S Arcangeli (998_CR140) 2020; 11
R Gardner (998_CR53) 2016; 127
S Amarnath (998_CR116) 2011; 3
CJ Turtle (998_CR127) 2016; 8
R Grosser (998_CR114) 2019; 36
998_CR35
C Tong (998_CR82) 2020; 136
NN Shah (998_CR143) 2020; 26
Y-R Li (998_CR66) 2022; 11
A Nowicki (998_CR68) 2021; 13
Y Dai (998_CR49) 2007; 67
N Wang (998_CR79) 2020; 135
M Asnani (998_CR21) 2020; 34
Y Lin (998_CR65) 2019; 12
NM Anderson (998_CR106) 2020; 30
K Takeda (998_CR90) 1998; 8
G Liu (998_CR108) 2020; 50
EK Moon (998_CR110) 2011; 17
S Rafiq (998_CR1) 2020; 17
EJ Orlando (998_CR15) 2018; 24
V Narayan (998_CR96) 2022; 28
DM Pardoll (998_CR39) 2012; 12
CJ Turtle (998_CR54) 2016; 126
L Giuffrida (998_CR98) 2021; 12
L Yang (998_CR70) 2020; 5
RG Majzner (998_CR9) 2018; 8
B Silva-Santos (998_CR4) 2015; 15
AD Cohen (998_CR16) 2019; 129
AM Tousley (998_CR130) 2023; 615
EK Moon (998_CR75) 2014; 20
CC Stamper (998_CR37) 2001; 410
X Wang (998_CR139) 2016; 127
J Lemoine (998_CR11) 2021; 14
JA Fraietta (998_CR137) 2018; 24
TF Tedder (998_CR13) 2009; 5
S Luo (998_CR73) 2022; 12
Y Ishida (998_CR117) 1992; 11
Y Akasaki (998_CR62) 2004; 173
EJ Wherry (998_CR133) 2011; 12
ER Hawkins (998_CR86) 2021; 15
CC Kloss (998_CR95) 2018; 26
E McGowan (998_CR81) 2020; 121
S Gessi (998_CR100) 2004; 65
M Ruella (998_CR77) 2016; 126
H Wang (998_CR122) 2019; 12
M Das (998_CR43) 2017; 276
L Monney (998_CR44) 2002; 415
998_CR121
P Sharma (998_CR38) 2015; 348
K Sakuishi (998_CR46) 2010; 207
998_CR94
S Cordoba (998_CR80) 2021; 27
M Kanduri (998_CR29) 2012; 7
X He (998_CR40) 2020; 30
Z Zhang (998_CR18) 2020; 8
A Mullard (998_CR8) 2022; 21
B Wang (998_CR31) 2014; 74
GA Rabinovich (998_CR58) 2007; 25
F Garrido (998_CR23) 2001; 83
K Sek (998_CR97) 2020; 53
998_CR105
B Seliger (998_CR28) 2000; 21
E Sotillo (998_CR19) 2015; 5
W Warda (998_CR52) 2021; 28
S Lian (998_CR48) 2019; 12
P Muranski (998_CR124) 2006; 3
References_xml – volume: 62
  start-page: 764
  year: 2013
  ident: 998_CR78
  publication-title: Histopathology
  doi: 10.1111/his.12079
  contributor:
    fullname: K Hwang
– ident: 998_CR94
  doi: 10.1172/jci.insight.133977
– volume: 15
  start-page: 81
  year: 2018
  ident: 998_CR12
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2017.166
  contributor:
    fullname: I Dagogo-Jack
– volume: 23
  start-page: 225
  year: 2005
  ident: 998_CR30
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.23.021704.115526
  contributor:
    fullname: LL Lanier
– volume: 136
  start-page: 1980
  year: 2020
  ident: 998_CR56
  publication-title: Blood
  doi: 10.1182/blood.2020005123
  contributor:
    fullname: Q Zhang
– volume: 6
  start-page: 1961
  year: 2022
  ident: 998_CR126
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2021006418
  contributor:
    fullname: VA Fabrizio
– ident: 998_CR35
  doi: 10.20944/preprints202102.0150.v1
– volume: 11
  start-page: 3887
  year: 1992
  ident: 998_CR117
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1992.tb05481.x
  contributor:
    fullname: Y Ishida
– volume: 20
  start-page: 3025
  year: 2017
  ident: 998_CR88
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.09.002
  contributor:
    fullname: B Hu
– volume: 171
  start-page: 205
  year: 2015
  ident: 998_CR55
  publication-title: Br J Haematol
  doi: 10.1111/bjh.13562
  contributor:
    fullname: AG Evans
– volume: 15
  start-page: 1243
  year: 2014
  ident: 998_CR67
  publication-title: EMBO Rep
  doi: 10.15252/embr.201439246
  contributor:
    fullname: MW Pickup
– volume: 14
  start-page: 1140541
  year: 2023
  ident: 998_CR125
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1140541
  contributor:
    fullname: AX Wang
– volume: 173
  start-page: 4352
  year: 2004
  ident: 998_CR62
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.7.4352
  contributor:
    fullname: Y Akasaki
– volume: 7
  start-page: 12320
  year: 2016
  ident: 998_CR57
  publication-title: Nat Commun
  doi: 10.1038/ncomms12320
  contributor:
    fullname: E Jacoby
– volume: 348
  start-page: 56
  year: 2015
  ident: 998_CR38
  publication-title: Science
  doi: 10.1126/science.aaa8172
  contributor:
    fullname: P Sharma
– ident: 998_CR105
  doi: 10.3390/ijms21010157
– volume: 135
  start-page: 17
  year: 2020
  ident: 998_CR79
  publication-title: Blood
  doi: 10.1182/blood.2019000017
  contributor:
    fullname: N Wang
– volume: 415
  start-page: 536
  year: 2002
  ident: 998_CR44
  publication-title: Nature
  doi: 10.1038/415536a
  contributor:
    fullname: L Monney
– volume: 13
  start-page: 4178
  year: 2021
  ident: 998_CR68
  publication-title: Cancers (Basel).
  doi: 10.3390/cancers13164178
  contributor:
    fullname: A Nowicki
– volume: 65
  start-page: 711
  year: 2004
  ident: 998_CR100
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.65.3.711
  contributor:
    fullname: S Gessi
– volume: 24
  start-page: 1504
  year: 2018
  ident: 998_CR15
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0146-z
  contributor:
    fullname: EJ Orlando
– volume: 130
  start-page: 2295
  year: 2017
  ident: 998_CR148
  publication-title: Blood
  doi: 10.1182/blood-2017-06-793141
  contributor:
    fullname: KA Hay
– ident: 998_CR121
  doi: 10.1182/blood-2018-99-112572
– volume: 12
  start-page: 59
  year: 2019
  ident: 998_CR122
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-019-0746-1
  contributor:
    fullname: H Wang
– volume: 11
  start-page: 1217
  year: 2020
  ident: 998_CR140
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01217
  contributor:
    fullname: S Arcangeli
– volume: 8
  start-page: 383
  year: 1998
  ident: 998_CR90
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80543-9
  contributor:
    fullname: K Takeda
– volume: 6
  start-page: e1792
  year: 2015
  ident: 998_CR76
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2015.162
  contributor:
    fullname: Y Jiang
– volume: 17
  year: 2022
  ident: 998_CR84
  publication-title: Transl Oncol
  doi: 10.1016/j.tranon.2022.101342
  contributor:
    fullname: Y Liu
– volume: 24
  start-page: 1499
  year: 2018
  ident: 998_CR51
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0201-9
  contributor:
    fullname: M Ruella
– volume: 65
  start-page: 2081
  year: 2003
  ident: 998_CR101
  publication-title: Biochem Pharmacol
  doi: 10.1016/S0006-2952(03)00158-8
  contributor:
    fullname: DE Lukashev
– volume: 203
  start-page: 198
  year: 2019
  ident: 998_CR93
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1800033
  contributor:
    fullname: Y Liu
– volume: 410
  start-page: 608
  year: 2001
  ident: 998_CR37
  publication-title: Nature
  doi: 10.1038/35069118
  contributor:
    fullname: CC Stamper
– volume: 67
  start-page: 2908
  year: 2007
  ident: 998_CR49
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0082
  contributor:
    fullname: Y Dai
– volume: 24
  start-page: 99
  year: 2006
  ident: 998_CR59
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.24.021605.090737
  contributor:
    fullname: MO Li
– volume: 33
  start-page: 780
  year: 2010
  ident: 998_CR111
  publication-title: J Immunother
  doi: 10.1097/CJI.0b013e3181ee6675
  contributor:
    fullname: JA Craddock
– volume: 29
  start-page: 415
  year: 2015
  ident: 998_CR89
  publication-title: Leukemia
  doi: 10.1038/leu.2014.215
  contributor:
    fullname: HJ Pegram
– volume: 7
  start-page: 1
  year: 2017
  ident: 998_CR103
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-00462-8
  contributor:
    fullname: LJ Rupp
– volume: 27
  start-page: 121
  year: 2021
  ident: 998_CR71
  publication-title: Mol Med
  doi: 10.1186/s10020-021-00383-3
  contributor:
    fullname: P Allavena
– volume: 129
  start-page: 100
  year: 2017
  ident: 998_CR32
  publication-title: Blood
  doi: 10.1182/blood-2016-05-718395
  contributor:
    fullname: F Braig
– volume: 26
  start-page: 1855
  year: 2018
  ident: 998_CR95
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2018.05.003
  contributor:
    fullname: CC Kloss
– volume: 27
  start-page: 1797
  year: 2021
  ident: 998_CR80
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01497-1
  contributor:
    fullname: S Cordoba
– ident: 998_CR132
  doi: 10.3389/fimmu.2023.1206441
– volume: 129
  start-page: 474
  year: 2010
  ident: 998_CR135
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2010.03255.x
  contributor:
    fullname: JS Yi
– volume: 21
  start-page: 249
  year: 2022
  ident: 998_CR8
  publication-title: Nat Rev Drug Discov
  contributor:
    fullname: A Mullard
– volume: 89
  start-page: 121
  year: 2008
  ident: 998_CR47
  publication-title: J Neurooncol
  doi: 10.1007/s11060-008-9601-x
  contributor:
    fullname: Y Yao
– volume: 5
  start-page: 1282
  year: 2015
  ident: 998_CR19
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-15-1020
  contributor:
    fullname: E Sotillo
– volume: 33
  start-page: 74
  year: 2015
  ident: 998_CR92
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.3329
  contributor:
    fullname: KC Conlon
– volume: 136
  start-page: 1632
  year: 2020
  ident: 998_CR82
  publication-title: Blood
  doi: 10.1182/blood-2020-140907
  contributor:
    fullname: C Tong
– volume: 31
  start-page: 473
  year: 2017
  ident: 998_CR144
  publication-title: BioDrugs
  doi: 10.1007/s40259-017-0247-0
  contributor:
    fullname: M Ruella
– volume: 12
  start-page: 865
  year: 2021
  ident: 998_CR14
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21168-6
  contributor:
    fullname: T Rabilloud
– volume: 10
  start-page: 717
  year: 2012
  ident: 998_CR69
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2012.05.007
  contributor:
    fullname: JE Visvader
– volume: 276
  start-page: 97
  year: 2017
  ident: 998_CR43
  publication-title: Immunol Rev
  doi: 10.1111/imr.12520
  contributor:
    fullname: M Das
– volume: 20
  start-page: 128
  year: 2020
  ident: 998_CR134
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-019-0223-7
  contributor:
    fullname: A Kallies
– volume: 615
  start-page: 507
  year: 2023
  ident: 998_CR130
  publication-title: Nature
  doi: 10.1038/s41586-023-05778-2
  contributor:
    fullname: AM Tousley
– volume: 28
  start-page: 724
  year: 2022
  ident: 998_CR96
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01726-1
  contributor:
    fullname: V Narayan
– volume: 126
  start-page: 2123
  year: 2016
  ident: 998_CR54
  publication-title: J Clin Invest
  doi: 10.1172/JCI85309
  contributor:
    fullname: CJ Turtle
– volume: 50
  start-page: 712
  year: 2020
  ident: 998_CR108
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201948457
  contributor:
    fullname: G Liu
– volume: 3
  start-page: 111ra120
  year: 2011
  ident: 998_CR116
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.3003130
  contributor:
    fullname: S Amarnath
– volume: 7
  start-page: e1364828
  year: 2017
  ident: 998_CR41
  publication-title: Oncoimmunology.
  doi: 10.1080/2162402X.2017.1364828
  contributor:
    fullname: S Simon
– volume: 165
  start-page: 1853
  year: 2004
  ident: 998_CR60
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)63238-5
  contributor:
    fullname: G Gerlini
– volume: 12
  start-page: 492
  year: 2011
  ident: 998_CR133
  publication-title: Nat Immunol
  doi: 10.1038/ni.2035
  contributor:
    fullname: EJ Wherry
– volume: 25
  start-page: 267
  year: 2007
  ident: 998_CR58
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.25.022106.141609
  contributor:
    fullname: GA Rabinovich
– volume: 90
  start-page: 2541
  year: 1997
  ident: 998_CR91
  publication-title: Blood
  contributor:
    fullname: JP Leonard
– volume: 385
  start-page: 517
  year: 2015
  ident: 998_CR147
  publication-title: Lancet (London, England).
  doi: 10.1016/S0140-6736(14)61403-3
  contributor:
    fullname: DW Lee
– volume: 13
  start-page: 999549
  year: 2022
  ident: 998_CR64
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.999549
  contributor:
    fullname: Y-R Li
– volume: 36
  start-page: 471
  year: 2019
  ident: 998_CR114
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.09.006
  contributor:
    fullname: R Grosser
– volume: 74
  start-page: 5746
  year: 2014
  ident: 998_CR31
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-2563
  contributor:
    fullname: B Wang
– volume: 34
  start-page: 1202
  year: 2020
  ident: 998_CR21
  publication-title: Leukemia
  doi: 10.1038/s41375-019-0580-z
  contributor:
    fullname: M Asnani
– volume: 24
  start-page: 6185
  year: 2018
  ident: 998_CR149
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0426
  contributor:
    fullname: G Enblad
– volume: 207
  start-page: 2187
  year: 2010
  ident: 998_CR46
  publication-title: J Exp Med
  doi: 10.1084/jem.20100643
  contributor:
    fullname: K Sakuishi
– volume: 12
  start-page: 850
  year: 2022
  ident: 998_CR73
  publication-title: Biomolecules
  doi: 10.3390/biom12060850
  contributor:
    fullname: S Luo
– volume: 14
  start-page: 1
  year: 2021
  ident: 998_CR11
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01209-9
  contributor:
    fullname: J Lemoine
– volume: 40
  start-page: 187
  year: 2017
  ident: 998_CR20
  publication-title: J Immunother
  doi: 10.1097/CJI.0000000000000169
  contributor:
    fullname: J Fischer
– volume: 53
  start-page: 91
  year: 2020
  ident: 998_CR97
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2020.07.002
  contributor:
    fullname: K Sek
– volume: 21
  start-page: 524
  year: 2015
  ident: 998_CR112
  publication-title: Nat Med
  doi: 10.1038/nm.3833
  contributor:
    fullname: I Caruana
– volume: 28
  start-page: 1365
  year: 2021
  ident: 998_CR52
  publication-title: Cancer Gene Ther
  doi: 10.1038/s41417-020-00284-3
  contributor:
    fullname: W Warda
– volume: 112
  start-page: 491
  issue: Pt 4
  year: 1999
  ident: 998_CR102
  publication-title: J Cell Sci
  doi: 10.1242/jcs.112.4.491
  contributor:
    fullname: M Mirabet
– volume: 8
  start-page: 1219
  year: 2018
  ident: 998_CR9
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0442
  contributor:
    fullname: RG Majzner
– volume: 173
  start-page: 1731
  year: 2004
  ident: 998_CR61
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.3.1731
  contributor:
    fullname: M Kurte
– volume: 126
  start-page: 3814
  year: 2016
  ident: 998_CR77
  publication-title: J Clin Invest
  doi: 10.1172/JCI87366
  contributor:
    fullname: M Ruella
– volume: 21
  start-page: 455
  year: 2000
  ident: 998_CR28
  publication-title: Immunol Today
  doi: 10.1016/S0167-5699(00)01692-3
  contributor:
    fullname: B Seliger
– volume: 19
  start-page: 5636
  year: 2013
  ident: 998_CR120
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0458
  contributor:
    fullname: LB John
– volume: 11
  start-page: 1583
  year: 2022
  ident: 998_CR66
  publication-title: Cells
  doi: 10.3390/cells11091583
  contributor:
    fullname: Y-R Li
– volume: 6
  start-page: 74
  year: 2013
  ident: 998_CR42
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-6-74
  contributor:
    fullname: L Shi
– volume: 17
  start-page: 4719
  year: 2011
  ident: 998_CR110
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-0351
  contributor:
    fullname: EK Moon
– volume: 105
  start-page: 1172
  year: 2013
  ident: 998_CR27
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djt184
  contributor:
    fullname: P Leone
– volume: 5
  start-page: 572
  year: 2009
  ident: 998_CR13
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2009.184
  contributor:
    fullname: TF Tedder
– volume: 126
  start-page: 3130
  year: 2016
  ident: 998_CR119
  publication-title: J Clin Invest
  doi: 10.1172/JCI83092
  contributor:
    fullname: L Cherkassky
– volume: 105
  start-page: 241
  year: 2005
  ident: 998_CR141
  publication-title: Blood
  doi: 10.1182/blood-2004-06-2482
  contributor:
    fullname: DJJ Powell
– volume: 15
  start-page: 683
  year: 2015
  ident: 998_CR4
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3904
  contributor:
    fullname: B Silva-Santos
– volume: 12
  start-page: 230
  year: 2021
  ident: 998_CR72
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27870
  contributor:
    fullname: B Aramini
– volume: 127
  start-page: 2406
  year: 2016
  ident: 998_CR53
  publication-title: Blood
  doi: 10.1182/blood-2015-08-665547
  contributor:
    fullname: R Gardner
– volume: 3
  start-page: 1418
  year: 2022
  ident: 998_CR6
  publication-title: Nat Cancer
  doi: 10.1038/s43018-022-00484-w
  contributor:
    fullname: ML Davila
– volume: 17
  start-page: 147
  year: 2020
  ident: 998_CR1
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-019-0297-y
  contributor:
    fullname: S Rafiq
– volume: 10
  start-page: 342
  year: 2019
  ident: 998_CR50
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-1568-3
  contributor:
    fullname: EF Lee
– volume: 68
  start-page: 134
  year: 2016
  ident: 998_CR22
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.09.010
  contributor:
    fullname: M de Charette
– volume: 129
  start-page: 2210
  year: 2019
  ident: 998_CR16
  publication-title: J Clin Invest
  doi: 10.1172/JCI126397
  contributor:
    fullname: AD Cohen
– volume: 24
  start-page: 563
  year: 2018
  ident: 998_CR137
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0010-1
  contributor:
    fullname: JA Fraietta
– volume: 3
  start-page: 668
  year: 2006
  ident: 998_CR124
  publication-title: Nat Clin Pract Oncol
  doi: 10.1038/ncponc0666
  contributor:
    fullname: P Muranski
– volume: 178
  start-page: 5552
  year: 2007
  ident: 998_CR118
  publication-title: J Immunol
  doi: 10.4049/jimmunol.178.9.5552
  contributor:
    fullname: MR Nazareth
– volume: 182
  start-page: 106329
  year: 2022
  ident: 998_CR113
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2022.106329
  contributor:
    fullname: SM Sagnella
– volume: 127
  start-page: 3350
  year: 2016
  ident: 998_CR10
  publication-title: Blood
  doi: 10.1182/blood-2015-12-629089
  contributor:
    fullname: C Sun
– volume: 15
  start-page: 95
  year: 2021
  ident: 998_CR86
  publication-title: Biologics
  contributor:
    fullname: ER Hawkins
– volume: 23
  start-page: 18
  year: 2017
  ident: 998_CR142
  publication-title: Nat Med United States
  doi: 10.1038/nm.4241
  contributor:
    fullname: L Gattinoni
– volume: 4
  start-page: 43
  year: 1998
  ident: 998_CR63
  publication-title: Nat Med
  doi: 10.1038/nm0198-043
  contributor:
    fullname: B Agrawal
– volume: 26
  start-page: 1569
  year: 2020
  ident: 998_CR143
  publication-title: Nat Med
  doi: 10.1038/s41591-020-1081-3
  contributor:
    fullname: NN Shah
– volume: 367
  start-page: 446
  year: 2020
  ident: 998_CR128
  publication-title: Science
  doi: 10.1126/science.aay5967
  contributor:
    fullname: K Reinhard
– volume: 94
  start-page: 1569
  year: 2009
  ident: 998_CR25
  publication-title: Haematologica
  doi: 10.3324/haematol.2009.008862
  contributor:
    fullname: H-W Bernd
– volume: 26
  start-page: 2542
  year: 2018
  ident: 998_CR123
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2018.09.008
  contributor:
    fullname: C DeSelm
– volume: 83
  start-page: 117
  year: 2001
  ident: 998_CR23
  publication-title: Adv Cancer Res
  doi: 10.1016/S0065-230X(01)83005-0
  contributor:
    fullname: F Garrido
– volume: 39
  start-page: 44
  year: 2016
  ident: 998_CR24
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2015.12.007
  contributor:
    fullname: F Garrido
– volume: 20
  start-page: 4262
  year: 2014
  ident: 998_CR75
  publication-title: Clin cancer Res
  doi: 10.1158/1078-0432.CCR-13-2627
  contributor:
    fullname: EK Moon
– volume: 14
  start-page: 2749
  year: 2022
  ident: 998_CR104
  publication-title: Cancers
  doi: 10.3390/cancers14112749
  contributor:
    fullname: Y-R Li
– volume: 7
  start-page: 1435
  year: 2012
  ident: 998_CR29
  publication-title: Epigenetics
  doi: 10.4161/epi.22901
  contributor:
    fullname: M Kanduri
– volume: 131
  start-page: 58
  year: 2018
  ident: 998_CR34
  publication-title: Blood
  doi: 10.1182/blood-2017-06-741033
  contributor:
    fullname: B Rowshanravan
– volume: 127
  start-page: 2980
  year: 2016
  ident: 998_CR139
  publication-title: Blood
  doi: 10.1182/blood-2015-12-686725
  contributor:
    fullname: X Wang
– volume: 108
  start-page: 311
  year: 2006
  ident: 998_CR26
  publication-title: Blood
  doi: 10.1182/blood-2005-11-4742
  contributor:
    fullname: RA Roberts
– volume: 30
  start-page: 660
  year: 2020
  ident: 998_CR40
  publication-title: Cell Res
  doi: 10.1038/s41422-020-0343-4
  contributor:
    fullname: X He
– volume: 27
  start-page: 111
  year: 2007
  ident: 998_CR115
  publication-title: Immunity
  doi: 10.1016/j.immuni.2007.05.016
  contributor:
    fullname: MJ Butte
– volume: 8
  start-page: 2872
  year: 2009
  ident: 998_CR129
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0583
  contributor:
    fullname: LG Daenen
– volume: 30
  start-page: R921
  year: 2020
  ident: 998_CR106
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2020.06.081
  contributor:
    fullname: NM Anderson
– volume: 2
  start-page: 377
  year: 2018
  ident: 998_CR7
  publication-title: Nat Biomed Eng
  doi: 10.1038/s41551-018-0235-9
  contributor:
    fullname: L Labanieh
– volume: 410
  start-page: 604
  year: 2001
  ident: 998_CR36
  publication-title: Nature
  doi: 10.1038/35069112
  contributor:
    fullname: JC Schwartz
– volume: 12
  start-page: 9105
  year: 2019
  ident: 998_CR48
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S220196
  contributor:
    fullname: S Lian
– volume: 19
  start-page: 200
  year: 2020
  ident: 998_CR2
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0052-1
  contributor:
    fullname: N Shimasaki
– volume: 613
  start-page: 743
  year: 2023
  ident: 998_CR85
  publication-title: Nature
  doi: 10.1038/s41586-022-05593-1
  contributor:
    fullname: NL de Vries
– volume: 12
  start-page: 252
  year: 2012
  ident: 998_CR39
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3239
  contributor:
    fullname: DM Pardoll
– volume: 8
  start-page: 355116
  year: 2016
  ident: 998_CR127
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.aaf8621
  contributor:
    fullname: CJ Turtle
– volume: 56
  start-page: 552
  year: 2021
  ident: 998_CR145
  publication-title: Bone Marrow Transplant
  doi: 10.1038/s41409-020-01134-4
  contributor:
    fullname: VS Sheth
– volume: 11
  start-page: 39
  year: 2018
  ident: 998_CR33
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0582-8
  contributor:
    fullname: JA Marin-Acevedo
– volume: 17
  start-page: 709
  year: 2017
  ident: 998_CR99
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2017.86
  contributor:
    fullname: D Vijayan
– volume: 12
  start-page: 627764
  year: 2021
  ident: 998_CR131
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.627764
  contributor:
    fullname: R Hong
– volume: 12
  start-page: 3236
  year: 2021
  ident: 998_CR98
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-23331-5
  contributor:
    fullname: L Giuffrida
– volume: 10
  start-page: 590941
  year: 2020
  ident: 998_CR74
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.590941
  contributor:
    fullname: Z Ge
– volume: 5
  start-page: 8
  year: 2020
  ident: 998_CR70
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-0110-5
  contributor:
    fullname: L Yang
– ident: 998_CR146
  doi: 10.1038/s41551-023-01084-4
– volume: 207
  start-page: 2175
  year: 2010
  ident: 998_CR45
  publication-title: J Exp Med
  doi: 10.1084/jem.20100637
  contributor:
    fullname: J Fourcade
– volume: 129
  start-page: 2123
  year: 2019
  ident: 998_CR136
  publication-title: J Clin Invest
  doi: 10.1172/JCI125423
  contributor:
    fullname: OC Finney
– volume: 28
  start-page: 678
  year: 2022
  ident: 998_CR5
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01765-8
  contributor:
    fullname: AV Finck
– volume: 24
  start-page: 1160
  year: 2010
  ident: 998_CR87
  publication-title: Leukemia
  doi: 10.1038/leu.2010.75
  contributor:
    fullname: V Hoyos
– volume: 9
  start-page: 115
  year: 2018
  ident: 998_CR107
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-017-0061-0
  contributor:
    fullname: MB Schaaf
– ident: 998_CR83
  doi: 10.1016/j.ymthe.2022.11.019
– volume: 15
  start-page: 632
  year: 2013
  ident: 998_CR138
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2013.01.002
  contributor:
    fullname: SF Lacey
– volume: 12
  start-page: 868
  year: 2021
  ident: 998_CR17
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21177-5
  contributor:
    fullname: MK Samur
– volume: 8
  start-page: e001150
  year: 2020
  ident: 998_CR18
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001150
  contributor:
    fullname: Z Zhang
– volume: 12
  start-page: 76
  year: 2019
  ident: 998_CR65
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-019-0760-3
  contributor:
    fullname: Y Lin
– volume: 19
  start-page: 185
  year: 2020
  ident: 998_CR3
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0051-2
  contributor:
    fullname: S Depil
– volume: 121
  start-page: 109625
  year: 2020
  ident: 998_CR81
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2019.109625
  contributor:
    fullname: E McGowan
– volume: 66
  start-page: 803
  year: 2021
  ident: 998_CR109
  publication-title: Sci Bull
  doi: 10.1016/j.scib.2020.12.027
  contributor:
    fullname: L Jin
SSID ssj0015987
Score 2.4731512
SecondaryResourceType review_article
Snippet Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking...
Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as...
Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as...
SourceID doaj
proquest
gale
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 5
SubjectTerms Antigen presentation
Antigens
Apoptosis
Cancer
Cancer therapies
CAR-engineered T (CAR-T) cell therapy
Care and treatment
Cell death
Cell therapy
Cell-based immunotherapies (CBIs)
Chimeric antigen receptor (CAR)
Chimeric antigen receptors
Cytotoxicity
Development and progression
Down-regulation
Genetic engineering
Health aspects
Humans
Immune checkpoint
Immune checkpoint proteins
Immune Evasion
Immune system
Immunosuppression
Immunotherapy
Immunotherapy, Adoptive
Ligands
Lymphocytes
Metastasis
Mutation
Neoplasms - therapy
Peptides
Prospective Studies
Proteins
Receptors, Chimeric Antigen - metabolism
Tumor cells
Tumor Microenvironment
Tumor microenvironment (TME)
Tumors
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1BT90wDLYQEmiXiQGDMkCZNInDFNGmTV-yG0xDMAlOY-IWpYkrcelDvPeQ-PfYbfq0Bwcu6zFJq9SO689p_BngmyIIjYi5DIQdKEDRSlqtvNR1SWBjUqFvOTn5-qa-vK1-3-m7f0p98ZmwgR54ENwpTqJqQkNIwWDVtmjyJg_e6lhprbEaoFFux2Aq_T_QFEqPKTKmPp2RV1NWkj-SDImMNCtuqGfrf_tNfoU0e49zsQUfE1QUZ8MUP8EadtuwMRSPfN6Gzev0W3wH_l5xlgcKfPK8-SXuO8Eb8pJdVBT33JkSrZ5_iEXHFYc4C12EsZLKTPguim5K7WI2H9kjduH24tefn5cyFUyQgXDWXDbWTyhECdgaH40OTMXiDZloqY0PdMU2NlWITGJP0aipbYuxaW2BdR3IUMvPsN5NO9wHURacfOd9RIqnYhP4sGmhWqTwhBBVxAy-j_JzDwMvhuvjCVO7QdqOpO16aTuTwTmLeDmSOa37BtK0S5p272k6gxNWkGPLI0kEnxIIaMLMYeXOCOwUtipMnsHhykiymLDaParYJYudOWWZe47xXQZfl918J59C63C6SGMIsFqVwd6wNJavVNLTJ4SfD_7Hq36BD6pfrIUs1CGszx8XeETgZ94c9-v8BWAWAFI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9UwEB7WFcUX0fVWXSWC4INE2zRpE0FkFZdVWJ88sm8hTabLgvTouYjn3zvTy5Gji31s0tBOZjrfJJn5AJ4pgtCImMtI2IECFKOkMypIU5UENmqNoeXk5NPP1clMfzozZ3sw0R2NAlxeGtoxn9Rs8e3lrx-bt2Twb3qDt9WrJfks5SR5G8mAx0p7Ba4qTZE6H-XTf3YVjOsJ85jNmlBlnU9JNJeOseOo-nr-__61_8KivU86vgU3RzApjobZvw172B3AtYFecnMA10_HjfM78PUj54GgwJ-Bl8fERSd4yV6yE0vighvHVKzNa7HumJOI89RFnLhWliJ0SXRzui-Wq6m-xF2YHX_48v5EjpQKMhISW8nGhZqCmIitDcmayMVagiUjLo0Nka7UpkbHxGXuKV61lWsxNa0rsKoimXJ5D_a7eYcPQJQFp-eFkJAirtREPo5aqBYpgCHMlTCDF5P8_PehcobvIw5b-UHanqTte2l7m8E7FvG2J1e97m_MF-d-NCKPdVJNbAg1WtRtizZv8hicSdoYgzpk8JwnyLO2kCRiGFMM6IW5ypU_IjhUOF3YPIPDnZ5kU3G3eZpiP6mkV46r0zECzODptpmf5HNqHc7XYx-CtE5lcH9Qje0nlTR6TQj74f8HfwQ3VK-GhSzUIeyvFmt8TMBn1Tzptfk38wT7lA
  priority: 102
  providerName: Scholars Portal
Title Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
URI https://www.ncbi.nlm.nih.gov/pubmed/38217016
https://www.proquest.com/docview/2914286151
https://search.proquest.com/docview/2914252292
https://doaj.org/article/e7d2bcb0838e4ffe80b0ca95d4555e4a
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDLfYJhAvCMZXYZyChMQDitamTZvwgja020C6CSGG7i1KkxTtpd3Wu0n777Hb9NCBRB_ykKRR68Txz05sA7wTCKFDCCl3iB1QQZGCayksl2WOYKMqgm3IOXlxXp5dFF-XchkNbn28VjnticNG7TtHNvJDoSk2GMnfT1fXnLJG0elqTKGxA3uZqCpSvtT8dHOKIPWQII-yVyOKrNLJaUaVhz3KOaE5SihOIElxtSWYhvj9_-7Sf2HPQQbNH8OjCB7Z0TjbT-BeaPfh_phO8m4fHiziQflT-PmF_D4CC7eWzGHssmVkoucktDy7pMboenX3ka1bykFEfunMTblVemZbz9oO61m_muJJPIOL-cmPz2c8plDgDpHXitfaVqi0uNAo65V0FJzFKmTaXCrr8PGNrwvnKaw96qeq1E3wdaOzUJYOWTd_Drtt14aXwPKM3PGs9QE1LF87un6aiSagwoIYy4cEPkz0M1djpAwzaBiqNCO1DVLbDNQ2KoFjIvGmJ0W5Hiq6m18mMo0JlRe1qxElqlA0TVBpnTqrpS-klKGwCbynCTLEi0gJZ6NLAX4wRbUyRwh_Ml1kKk3gYKsn8pDbbp6m2EQe7s2fFZfA200zvUn30trQrWMfhLBaJPBiXBqbX8px9AoR9av_D_4aHophGWY8Ewewu7pZhzcIdFb1DHaqZTUb1vQM9o5Pzr99nw1GAyxPlxmWi0L9BoGM_Zo
link.rule.ids 315,783,787,867,2109,12068,12777,21400,24330,27936,27937,31731,31732,33385,33386,33756,33757,43322,43612,43817
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDLdgiI8XBINBYUCQkHhA0fqVXsILGojjBrs9bWhvUZq4aC_tWO-Q9t9jt-mhA4k-JmnUOnb8sxPbAG9ygtCImEpP2IEMFJVLo3InVVUQ2JiV6BoOTl6eVIuz8uu5Oo8Otz5eq5z2xGGjDp1nH_lBbjg3GOvfD5c_JVeN4tPVWELjJtwqC9LVHCk-_7I5RVBmKJDH1asJRc7SKWhGVwc96bncSNJQkkGSlnpLMQ35-__dpf_CnoMOmj-A-xE8isNxtR_CDWx34fZYTvJ6F-4s40H5I_h-xHEfKPCXY3eYuGgFu-glK60gLrgzhl5dvxfrlmsQcVy68FNtlV64Noi2o3bRr6Z8Eo_hbP759NNCxhIK0hPyWsnauBkZLR4b7YJWnpOzOE1CWyjtPD2hCXXpA6e1J_tUV6bBUDcmw6ryJLrFHuy0XYtPQRQZh-M5F5AsrFB7vn6a5Q2SwUIYK2AC7yb62csxU4YdLAxd2ZHalqhtB2pbncBHJvFmJGe5Hhq6qx82Co3FWchrXxNK1Fg2Deq0Tr0zKpRKKSxdAm95gSzLIlHCuxhSQB_MWa3sIcGfzJSZThPY3xpJMuS3u6cltlGGe_uH4xJ4venmN_leWovdOo4hCGvyBJ6MrLH5pYJmnxGifvb_yV_B3cXp8tgeH518ew738oElM5nl-7CzulrjCwI9q_rlwNm_AdBT-zs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immune+evasion+in+cell-based+immunotherapy%3A+unraveling+challenges+and+novel+strategies&rft.jtitle=Journal+of+biomedical+science&rft.au=Yan-Ruide+Li&rft.au=Halladay%2C+Tyler&rft.au=Yang%2C+Lili&rft.date=2024-01-12&rft.pub=BioMed+Central&rft.issn=1021-7770&rft.eissn=1423-0127&rft.volume=31&rft.spage=1&rft_id=info:doi/10.1186%2Fs12929-024-00998-8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1423-0127&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1423-0127&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1423-0127&client=summon